Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma Business
-
By Kwame Mensah — Last month, King Pharmaceuticals, Inc. announced that it is extending its previously announced tender offer for all outstanding shares of Class A Common Stock of Alpharma Inc. (representing a total equity value of approximately $1.6 billion and an enterprise value of approximately $1.4 billion) until 5:00 pm, Eastern time, on…
-
By Jason Derry — Icon plc has announced its acquisition of Prevalere Life Sciences Inc., a move that will expand Icon's bioanalytics and immunoassay business in the United States. Prevalere, identified in the announcement as a wholly owned subsidiary of ORS Labs Inc, is a New York-based contract research organization that provides consulting and…
-
By Kevin E. Noonan — EvaluatePharma, a London-based company providing forecasting and industry analysis to the biotech and pharma sector, released a report today predicting the big pharma landscape in 2014, based on industry trends, current and prospective drug pipelines, acquisitions and partnering and the predicted "patent cliff" that will occur as blockbuster…
-
By Sherri Oslick — In a transaction merging two major players in the generic pharmaceutical arena, Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced late last week that they have entered into an agreement by which Teva will acquire Barr for $7.46 billion plus the assumption of $1.5 billion in debt. The…
-
By Christopher P. Singer — On Monday, FierceBiotech published its annual "Fierce 15" list of what it considers to be among the most promising of the up-and-coming companies in the biotechnology industry. FierceBiotech, a daily biotech industry news provider, has been publishing the Fierce 15 since 2003. The companies below (listed alphabetically) were…
-
By Donald Zuhn — With the BIO International Convention less than a month away, a report in the San Francisco Chronicle is predicting that the U.S. biotech industry may be looking at some rough times ahead. The Chronicle’s prediction is interesting given its citation of a recent Ernst & Young study that noted…
-
By Donald Zuhn — The Senate patent reform bill may or may not be dead (see "Bush Administration Continues Attempt to Destroy U.S. Patent System"). However, if the bill’s time has indeed come and gone (at least as far as the 110th Congress is concerned), its passing will be due in no small…
-
By Donald Zuhn — Earlier this month, the monthly healthcare marketing publication Medical Marketing & Media (MM&M) announced the release of The Pharma Report 2008, MM&M’s list of the top twenty pharmaceutical companies (as determined by U.S drug sales in 2007). According to MM&M’s report, the top twenty pharma companies for 2007 were:…
-
By Donald Zuhn — In March, we reported on the lobbying expenditures for a number of biotech and pharmaceutical companies in 2007. For example, we noted that Millennium Pharmaceuticals had spent $1.28 million, Genentech $1.8 million, and AstraZeneca $4.1 million in 2007. Topping each of these companies, however, was Abbott Laboratories, based in…
-
By Donald Zuhn — Last Tuesday, GlaxoSmithKline and Sirtris Pharmaceuticals announced that the companies had entered into a definitive agreement under which GlaxoSmithKline would acquire Sirtris Pharmaceuticals for approximately $720 million. The acquisition is motivated by GSK’s desire to enhance its metabolic, neurology, immunology, and inflammation research efforts by utilizing Sirtris’ expertise in…
Patent Docs 